The purpose of the trial is to find out how well tarlatamab can shrink or control the brain tumors. Participants will receive the medication on a regular schedule, and doctors will look at the brain with MRI scans after six weeks and then every six weeks, while chest and abdominal areas will be examined with CT scans at the same intervals. The study follows patients for several months to observe both short‑term and longer‑term effects.

At each clinic visit, safety checks are performed and any side effects are recorded, and the overall participation period may extend up to about a year, depending on continued treatment and follow‑up imaging.

The purpose of this study is to compare how well BNT327 works compared to atezolizumab when each is given with chemotherapy, specifically by looking at how long participants live after starting treatment. The study will also examine how long participants live without their cancer getting worse, how many participants see their tumors shrink or disappear, and how long these responses last. Additionally, the study will monitor side effects and how the treatments affect quality of life and cancer-related symptoms such as coughing and shortness of breath.

This is a randomized study, which means participants will be assigned by chance to receive either BNT327 with chemotherapy or atezolizumab with chemotherapy. The study is double-blinded, meaning neither the participants nor their doctors will know which treatment group they are in during the study. Participants will receive treatment for up to 48 weeks or longer depending on how they respond to the treatment. Throughout the study, participants will have regular visits where their health, tumor size, and any side effects will be monitored through physical examinations, blood tests, imaging scans, and questionnaires about their well-being and symptoms.

The purpose of this study is to find out the best dose of IDP-121 when it is given with chemotherapy and to see how well this combination works in treating small cell lung cancer that has come back. The study has two parts. In the first part, different doses of IDP-121 will be tested to find the highest dose that can be given safely and the best dose to use in the second part of the study. In the second part, more patients will receive the chosen dose of IDP-121 with chemotherapy to learn more about how well it works in shrinking or controlling the cancer.

During the study, patients will receive IDP-121 as an infusion into a vein along with their chemotherapy treatment. The study will check how patients respond to the treatment by looking at whether the cancer shrinks, stays the same, or grows. Doctors will also monitor patients for any side effects and will perform regular tests including blood tests, heart function tests using echocardiogram, physical examinations, and electrocardiograms to check the electrical activity of the heart. The study will also measure how long the treatment keeps working if the cancer responds and how long patients live.

The purpose of this study is to evaluate how well Tarlatamab works in treating patients with extensive stage small-cell lung cancer who have poor performance status and to see if this treatment is practical and manageable for these patients. The study will look at how many patients are alive after twelve months of treatment, which is the main focus of the research. It will also examine how long patients live overall, how long they live without their cancer getting worse, how many patients experience shrinkage of their tumors, and how many patients can tolerate the treatment until their first disease check-up.

During the study, patients will receive Tarlatamab treatment over a period of up to twelve months. The doctors will monitor how well the treatment works by checking if tumors shrink or disappear, including tumors that may have spread to the brain. They will also carefully watch for any side effects and assess the safety of the treatment. Additionally, the study will measure how the treatment affects patients’ quality of life and their ability to perform daily activities. The research will also track how long it takes before patients need to start a different type of cancer treatment.

The purpose of the study is to understand how well Tarlatamab works in treating these cancers. Tarlatamab is a special type of treatment known as a bispecific T-cell engager (BiTE) molecule, which is designed to help the body’s immune system target and fight cancer cells. The study will involve giving the treatment to patients through an intravenous infusion, which means it will be administered directly into the bloodstream. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects.

Participants in the study will receive the treatment over a period of time, and their response to the treatment will be monitored. This includes looking at how the cancer responds to the treatment and any side effects that may occur. The study aims to gather information on how effective Tarlatamab is in treating these types of cancer and to better understand the body’s response to the treatment. The study will also include biomarker analysis, which involves studying certain biological markers in the body to understand how they relate to the treatment’s effectiveness and any resistance that may develop.

The purpose of this study is to explore the safety and effectiveness of these two drugs when used together in patients whose SCLC has returned after initial treatment. The study is divided into two stages. In the first stage, researchers aim to find the best dose of lurbinectedin to use with pembrolizumab. In the second stage, they will assess how well this combination works in treating the cancer. Participants will receive the medications through an intravenous infusion, which means the drugs are given directly into a vein.

Throughout the study, participants will be monitored for any side effects and the response of their cancer to the treatment. This will involve regular check-ups and imaging tests like CT scans or MRI to track the size and spread of the cancer. The study will help determine if this combination of treatments can provide a new option for patients with relapsed SCLC.

The purpose of this research is to determine if this combination of medications is safe and effective for treating advanced Small Cell Lung Cancer. The study is divided into two parts. The first part aims to find the right dose of the medications that can be safely given together. The second part evaluates how well the treatment works in fighting the cancer.

During the study, participants receive regular infusions of both medications. Their cancer is monitored through regular imaging tests every six weeks to check how the treatment is working. The study team tracks any side effects and how well patients respond to the treatment. Some patients may also provide blood and tissue samples to help researchers better understand how the medications work in the body.

The purpose of the study is to test the feasibility and effectiveness of this treatment plan. The treatment will start with a combination of chemotherapy and radiotherapy, which is a type of cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors. This will be followed by a more targeted form of radiotherapy called stereotactic radiotherapy, which aims to precisely target cancer cells while sparing healthy tissue. The study will also look at how well this treatment plan can help patients live longer without the cancer getting worse over a period of 12 months.

Participants in the study will receive the treatment over a period of time, with the initial phase involving chemotherapy and radiotherapy, followed by maintenance therapy with Durvalumab. The study aims to gather information on how well patients respond to this combination of treatments and whether it can improve their quality of life and survival rates. The trial is expected to continue until 2026, with recruitment starting in 2024.